Will 2016 Bring US Biosimilar Reimbursement Clarity?
This article was originally published in Scrip
Executive Summary
As the emerging US biosimilars marketplace takes shape, payers are expected to "actively" learn – both clinically and economically – where the opportunities of those products may meet the ongoing reality of the US health care system, and they likely will adjust reimbursement mechanisms over time accordingly, the authors of a new report sponsored by Amgen Inc. said, declaring 2016 promises to bring greater clarity to the American landscape for the copycat biologics.